Short Bowel SyndromePhase 2NCT07704047
A Clinical Study of FT1 in Patients With Short Bowel Syndrome
A Phase 2 study testing FT1 in people with Short Bowel Syndrome and SBS, run by Chongqing Peg-Bio Biopharm Co., Ltd. at 1 site in China.
Trial summary
The goal of this clinical trial is to learn if FT1 is safe and works to treat short bowel syndrome (SBS) in adults. It will also learn about the PK/PD profile of FT1. Researchers will compare FT1 to a placebo (a look-alike substance that contains no drug) to see if FT1 is safe and effective in patients with SBS. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Short Bowel Syndrome, SBS
- What is being tested?
- FT1
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 8 participants
- Where
- 1 siteChina
- Study dates
- 30 Aug 2026to 15 Apr 2027
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years, male or female.
- SBS secondary to surgical resection of the small intestine, screened for at least 12 months after pre intestinal resection surgery;
- Stable weight before screening; For patients requiring parenteral support (PS), PS volume remained stable (with changes in volume or energy content<25%) within 14 days prior to randomization;
- Willing to undergo colonoscopy and remove polyps assessed by researchers to be at risk of cancer;
- During the trial period, there were no plans to perform any major abdominal surgeries (such as intestinal resection exceeding 10% or surgeries that alter intestinal anatomy, such as stoma surgery);
- During the baseline metabolic balance study, the average daily fecal wet rearrangement amount was ≥ 800g;
Who cannot join
- Having undergone major abdominal surgery (such as intestinal resection exceeding 10%) within the past 6 months prior to screening;
- History of clinically significant intestinal adhesions and/or chronic abdominal pain;
- History of persistent radiation enteritis, celiac disease, refractory diarrhea, etc;
- Patients with malignant tumors within the past 5 years (excluding fully treated cervical carcinoma in situ, basal cell or squamous cell carcinoma of the skin, local prostate cancer after radical surgery, and ductal carcinoma in situ of the breast after radical surgery);
- History of gallstones in the past 3 years, except for those who have undergone cholecystectomy for gallstones; Acute cholecystitis or biliary obstruction related diseases that have not been treated within the previous month or during the screening period;
- IBD patients with active inflammatory bowel disease (IBD), or requiring increased or altered immunosuppressive therapy in the past 3 months, or receiving biologic therapy in the past 6 months;
Show all 13Show fewer
- Occurrence of central venous catheter-related bloodstream infections within 2 months prior to and during the screening period;
- Patients diagnosed with decompensated heart failure (NYHA grade III or above) and/or unstable angina and/or myocardial infarction from 6 months prior to screening until the first administration of the study drug;
- Screening for individuals with rectal bleeding within the first 3 months;
- Individuals with absorption instability caused by cystic fibrosis, untreated megacolon disease, or known DNA abnormalities (such as familial adenomatous polyposis, Fanconi syndrome);
- Serious active, uncontrolled, untreated, acute onset systemic diseases (such as cardiovascular, respiratory, renal, infectious, endocrine, liver or central nervous system, etc.);
- Pregnant or breastfeeding women.
- The investigator believes the subject is unsuitable for participating in this clinical study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
General Hospital of Eastern Theater Command
Nanjing, Jiangsu, 210002
Xinying Wang, 86-13983367811, sunj@pegbiocq.com
Xinying Wang
About this study
Official title: A Randomized, Double-blind, Crossover, Placebo-controlled Phase IIa Clinical Study Evaluating the Efficacy and Safety of Recombinant Acylated Glucagon Like Peptide-2 Analog (FT1) for Injection in Patients With Short Bowel Syndrome
The goal of this clinical trial is to learn if FT1 is safe and works to treat short bowel syndrome (SBS) in adults. It will also learn about the PK/PD profile of FT1.
Researchers will compare FT1 to a placebo (a look-alike substance that contains no drug) to see if FT1 is safe and effective in patients with SBS.
Participants will
- Receive multiple injections of FT1 or placebo according to weight.
- Visit the clinic for assessment.
Read the detailed description
In this placebo-controlled, double-blind, randomized, crossover phase 2 trial, 8 adult SBS patients are treated with once-weekly FT1 or placebo (1:1) for 5 weeks, followed by a washout period of at least 6 weeks, and then the alternate treatment for a further 5 weeks.
Efficacy is evaluated through a 72 hour metabolic balance study conducted at baseline and at the end of each treatment cycle.
- Conditions
- Short Bowel Syndrome, SBS
- Being tested
- FT1, Placebo
- Keywords
- short bowel syndrome, SBS, GLP-2, FT1
- Medical subject headings
- Short Bowel Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FT1Drug
FT1 treatment, once weekly for 5 weeks
PlaceboDrug
Placebo, once weekly for 5 weeks
| Study group | Role | What they receive |
|---|---|---|
| FT1 | Experimental | FT1 will be administered subcutaneously once a week for 5 weeks during each treatment cycle. Receives: Drug: FT1 |
| FT1 Placebo | Placebo comparator | FT1 Placebo will be administered subcutaneously once a week for 5 weeks during each treatment cycle. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Treatment-related Adverse Events
To evaluate the adverse events as characterized by type, frequency, severity as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 6.0, timing, seriousness, and relationship to study therapy after administration.
Measured: From the first administration to study completion, appropriately 5 months.
Changes in fecal wet weight from baseline to the end of treatment
The difference in changes in fecal wet weight in the 72-hour metabolic balance study after treatment compared to baseline
Measured: At the end of the second cycle (each cycle is 5 weeks, with a washout period of at least 6 weeks between two cycles)
Secondary outcomes (4)
Changes in urine volume from baseline to the end of treatment
The difference in changes in urine volume in the 72-hour metabolic balance study after treatment compared to baseline
Measured: At the end of the second cycle (each cycle is 5 weeks, with a washout period of at least 6 weeks between two cycles)
The Area Under the Curve from dosing to the time of the last measured concentration (AUC0-t)
Pharmacokinetic parameter
Measured: Up to 8 days, from Day 29 (the last dose administration) to Day 36 (7 days after the last dose) in each treatment cycle (each cycle is 5 weeks)
Maximum plasma concentration (Cmax)
Pharmacokinetic parameter
Measured: Up to 8 days, from Day 29 (the last dose administration) to Day 36 (7 days after the last dose) in each treatment cycle (each cycle is 5 weeks)
Changes in L-citrulline levels in plasma
Pharmacodynamic parameter
Measured: From Day 1 of the first cycle to the end of the second cycle (each cycle is 5 weeks, with a washout period of at least 6 weeks between two cycles)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jul 2026
- Study start30 Aug 2026 (estimated)
- Primary completion15 Apr 2027 (estimated)
- Study completion15 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Short Bowel SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- In this placebo-controlled, double-blind, randomized, crossover trial, SBS patients are treated with once-weekly FT1 or placebo (1:1) for 5 weeks, followed by a washout period of at least 6 weeks, and then the alternate treatment for a further 5 weeks.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 8 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07704047
- Sponsor's protocol ID
- FT1-A201
- Status last verified
- Jul 2026
- First submitted
- 3 Jul 2026
- Last updated
- 15 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-blind, Crossover, Placebo-controlled Phase IIa Clinical Study Evaluating the Efficacy and Safety of Recombinant Acylated Glucagon Like Peptide-2 Analog (FT1) for Injection in Patients With Short Bowel Syndrome
- ClinicalTrials.gov ID
- NCT07704047
- Acronym / sponsor ID
- FT1-A201
- Conditions
- Short Bowel Syndrome, SBS
- Keywords
- short bowel syndrome, SBS, GLP-2, FT1
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 8 participants (estimated)
- Lead sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 30 Aug 2026 (estimated)
- Primary completion
- 15 Apr 2027 (estimated)
- Study completion
- 15 Apr 2027 (estimated)
- First posted
- 15 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if FT1 is safe and works to treat short bowel syndrome (SBS) in adults. It will also learn about the PK/PD profile of FT1.
Researchers will compare FT1 to a placebo (a look-alike substance that contains no drug) to see if FT1 is safe and effective in patients with SBS.
Participants will
- Receive multiple injections of FT1 or placebo according to weight.
- Visit the clinic for assessment.
Detailed description
In this placebo-controlled, double-blind, randomized, crossover phase 2 trial, 8 adult SBS patients are treated with once-weekly FT1 or placebo (1:1) for 5 weeks, followed by a washout period of at least 6 weeks, and then the alternate treatment for a further 5 weeks.
Efficacy is evaluated through a 72 hour metabolic balance study conducted at baseline and at the end of each treatment cycle.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- In this placebo-controlled, double-blind, randomized, crossover trial, SBS patients are treated with once-weekly FT1 or placebo (1:1) for 5 weeks, followed by a washout period of at least 6 weeks, and then the alternate treatment for a further 5 weeks.
| Arm | Type | Receives |
|---|---|---|
| FT1 | Experimental | Drug: FT1FT1 will be administered subcutaneously once a week for 5 weeks during each treatment cycle. |
| FT1 Placebo | Placebo comparator | Drug: PlaceboFT1 Placebo will be administered subcutaneously once a week for 5 weeks during each treatment cycle. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age ≥ 18 years, male or female.
- SBS secondary to surgical resection of the small intestine, screened for at least 12 months after pre intestinal resection surgery;
- Stable weight before screening; For patients requiring parenteral support (PS), PS volume remained stable (with changes in volume or energy content<25%) within 14 days prior to randomization;
- Willing to undergo colonoscopy and remove polyps assessed by researchers to be at risk of cancer;
- During the trial period, there were no plans to perform any major abdominal surgeries (such as intestinal resection exceeding 10% or surgeries that alter intestinal anatomy, such as stoma surgery);
Key exclusion criteria (13 listed)
- Having undergone major abdominal surgery (such as intestinal resection exceeding 10%) within the past 6 months prior to screening;
- History of clinically significant intestinal adhesions and/or chronic abdominal pain;
- History of persistent radiation enteritis, celiac disease, refractory diarrhea, etc;
- Patients with malignant tumors within the past 5 years (excluding fully treated cervical carcinoma in situ, basal cell or squamous cell carcinoma of the skin, local prostate cancer after radical surgery, and ductal carcinoma in situ of the breast after radical surgery);
- History of gallstones in the past 3 years, except for those who have undergone cholecystectomy for gallstones; Acute cholecystitis or biliary obstruction related diseases that have not been treated within the previous month or during the screening period;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FT1FT1 treatment, once weekly for 5 weeks | Drug | FT1 |
| PlaceboPlacebo, once weekly for 5 weeks | Drug | FT1 Placebo |
Primary outcome
Treatment-related Adverse Events
Time frame: From the first administration to study completion, appropriately 5 months.
To evaluate the adverse events as characterized by type, frequency, severity as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 6.0, timing, seriousness, and relationship to study therapy after administration.
Changes in fecal wet weight from baseline to the end of treatment
Time frame: At the end of the second cycle (each cycle is 5 weeks, with a washout period of at least 6 weeks between two cycles)
The difference in changes in fecal wet weight in the 72-hour metabolic balance study after treatment compared to baseline
4 secondary outcomes
Changes in urine volume from baseline to the end of treatment
Time frame: At the end of the second cycle (each cycle is 5 weeks, with a washout period of at least 6 weeks between two cycles)
The Area Under the Curve from dosing to the time of the last measured concentration (AUC0-t)
Time frame: Up to 8 days, from Day 29 (the last dose administration) to Day 36 (7 days after the last dose) in each treatment cycle (each cycle is 5 weeks)
Maximum plasma concentration (Cmax)
Time frame: Up to 8 days, from Day 29 (the last dose administration) to Day 36 (7 days after the last dose) in each treatment cycle (each cycle is 5 weeks)
Changes in L-citrulline levels in plasma
Time frame: From Day 1 of the first cycle to the end of the second cycle (each cycle is 5 weeks, with a washout period of at least 6 weeks between two cycles)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jul 2026.
Related trials for Short Bowel Syndrome
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Active, not recruitingPhase 3
Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition
Short Bowel Syndrome
Not yet recruitingPhase 2
Efficacy and Safety of TRA16 Administered Orally in Patients With Enteric Hyperoxaluria (EH).
Enteric Hyperoxaluria
RecruitingPhase 3
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
Short Bowel Syndrome
Active, not recruitingObservational study
Registry for Participants With Short Bowel Syndrome
Short Bowel Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing FT1 in people with Short Bowel Syndrome and SBS, run by Chongqing Peg-Bio Biopharm Co., Ltd. at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jing Sun (+86-13983367811, sunj@pegbiocq.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Treatment-related Adverse Events (time frame: From the first administration to study completion, appropriately 5 months.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jul 2026.